Elewski BE, Baker CS, Crowley JJ, et al. - Researchers evaluated the effectiveness and safety of adalimumab (ADA) (Humira [AbbVie Inc, North Chicago, IL]) long-term treatment (52 weeks) in patients with moderate-to-severe plaque psoriasis and concomitant moderate-to-severe psoriasis of the fingernail in this phase-3, randomized, placebo-controlled trial. Reporting results from the first 26 weeks (Period A). In the subsequent 26-week open-label extension (OLE) period, participants receiving 40 mg ADA every other week or placebo in Period A persisted or switched to 40 mg ADA every other week. Of the initially randomized 217 patients in Period A, 188 entered the OLE after completion or early escape from Period A. It was noted that serious adverse event and serious infection rates for the All-ADA Population were 6.9% and 3.4%, respectively. Long-term effectiveness and improvement in signs and symptoms of nail disease were shown after every-other-week ADA treatment in this population of psoriasis patients with concomitant, moderate-to-severe nail psoriasis, including incremental improvements in the rate of total clearance of nail disease. For patients receiving at least one dose of ADA over 52 weeks, no new safety hazards have been recognized.